primarily hematologic, including neutropenia, thrombocytopenia and anemia.
Infusion-related toxicities were associated with pre-administration of
rituximab. The risk of hematologic toxicity correlated with the degree of
bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute
myelogenous leukemia was observed in 2 percent of patients (8 to 34 months
after treatment). Zevalin should only be used by health care professionals
qualified by training and experience in the safe use of radionuclides.
Patients and healthcare professionals can visit http://www.zevalin.com
for more information.
About Non-Hodgkin's Lymphoma
Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of
white blood cells and normally spreads through the lymphatic system, a
system of vessels that drains fluid from the body. NHL can be broadly
classified into two main forms -- aggressive NHL, a rapidly spreading acute
form of the disease, and indolent NHL, which progresses more slowly.
According to the SEER CanQuest Database and the American Cancer Society, in
2005, the prevalence of indolent NHL in the United States was 282,025 with
24,490 newly diagnosed patients. The prevalence of aggressive NHL in the
United States was 99,880 with 31,900 newly diagnosed patients.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed
to developing an integrated portfolio of oncology products aimed at making
cancer more treatable. For additional information, please visit
On Wednesday, June 18, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central
European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI)
Page: 1 2 3 4 5 6 Related biology technology :1
|SOURCE Cell Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents2
. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center3
. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide4
. Chromos enters into loan and lending arrangements5
. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline6
. CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order7
. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services8
. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil9
. Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers10
. Finesse Solutions Expands by Opening Sales and Service Centers11
. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor